Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome
Approximately 30% of children with idiopathic nephrotic syndrome develop a complicated course with frequent relapses or steroid dependency. Rituximab, a B cell depleting monoclonal antibody, is a safe and effective alternative to steroids or other immunosuppressants for achieving and maintaining rem...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
30 November 2020
|
| In: |
BMC nephrology
Year: 2020, Volume: 21, Pages: 1-11 |
| ISSN: | 1471-2369 |
| DOI: | 10.1186/s12882-020-02153-5 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12882-020-02153-5 Verlag, kostenfrei, Volltext: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-020-02153-5 
|
| Author Notes: | Biswanath Basu, Stella Preussler, Anja Sander, T.K.S. Mahapatra and Franz Schaefer |
| Summary: | Approximately 30% of children with idiopathic nephrotic syndrome develop a complicated course with frequent relapses or steroid dependency. Rituximab, a B cell depleting monoclonal antibody, is a safe and effective alternative to steroids or other immunosuppressants for achieving and maintaining remission in this population at short term. Despite the good initial response relapses inevitably occur after regeneration of B lymphocytes, necessitating either repeat courses of rituximab or addition of another steroid-sparing immunosuppressant. |
|---|---|
| Item Description: | Gesehen am 08.01.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1471-2369 |
| DOI: | 10.1186/s12882-020-02153-5 |